- €941.31m
- €913.90m
- €19.52m
Brief: MedinCell Targets Anti-Malaria Injectable First Clinical Trial In 2023
Brief: MedinCell Confirms Safety Of Continuous Administration of Ivermectin
Brief: MedinCell: Mdc-CWM Clinical Phase 3 Will Start In 2021
Brief: Medincell Publishes Ivermectin Safety Expert Analysis
Brief: Medincell Announces Capital Increase Of Ac. 30 Million Euros
Brief: Medincell Announces Three New Products Entering Regulatory Development
Brief: Medincell Announces Transfer Of Euronext Paris Shares From Compartment C To B On Jan 29, 2021
Brief: MedinCell To Resume Trading On Euronext Paris
Brief: Teva, Medincell Announce Positive Results For Risperidone Registration Trial
Brief: Medincell Reports H1 Net Loss Of 10.8 Million Euros
Brief: Medincell Initiates First Clinical Trial Of Its Covid-19 Prevention Program
Brief: Medincell Raises EUR 15.6 Million In Capital Increase
Brief: Medincell Launches Capital Increase Of 11 Millions Euros
Brief: Euronext announces quarterly revision of French indices
Brief: Medincell FY Operating Loss Widens To 19.3 Million Euros
Brief: Medincell Secures Non-Dilutive Financing Of 10.9 Million Euros
Brief: Medincell: Product Portfolio Progresses Well Amid COVID-19 Pandemic
Brief: Medincell Launches Regulatory Development Of Mdc-WWM Program
Brief: MedinCell Receives $6.4 Million Grant From Unitaid To Fight Malaria